PD173074

TargetMol
Product Code: TAR-T2642
Supplier: TargetMol
CodeSizePrice
TAR-T2642-5mg5mg£99.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T2642-10mg10mg£112.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T2642-1mL1 mL * 10 mM (in DMSO)£114.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T2642-25mg25mg£144.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T2642-50mg50mg£185.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T2642-100mg100mg£258.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T2642-200mg200mg£402.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T2642-500mg500mg£624.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT

Overview

Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃

Images

1 / 1

Further Information

Bioactivity:
PD173074 is an effective FGFR1 inhibitor (IC50: 25 nM) and also inhibits VEGFR2 (IC50: 100-200 nM) in cell-free assays. The selectivity is higher ~1000-fold for FGFR1 than PDGFR and c-Src.
CAS:
219580-11-7
Formula:
C28H41N7O3
Molecular Weight:
523.682
Pathway:
Angiogenesis; Apoptosis; JAK/STAT signaling; Tyrosine Kinase/Adaptors
Purity:
0.9821
SMILES:
CCN(CC)CCCCNc1ncc2cc(c(NC(=O)NC(C)(C)C)nc2n1)-c1cc(OC)cc(OC)c1
Target:
Apoptosis; EGFR; VEGFR; FGFR; IGF-1R; Src

References

1. Mohammadi M, et al. EMBO J, 1998, 17(20), 5896-5904. 2. Skaper SD, et al. J Neurochem, 2000, 75(4), 1520-1527. 3. Bansal R, et al. J Neurosci Res, 2003, 74(4), 486-493. 4. Trudel S, et al. Blood, 2004, 103(9), 3521-3528. 5. Pardo OE, et al. Cancer Res, 2009, 69(22), 8645-8651. 6. Zheng Y, et al. Inhibition of FGFR Signaling With PD173074 Ameliorates Monocrotaline-induced Pulmonary Arterial Hypertension and Rescues BMPR-II Expression. J Cardiovasc Pharmacol. 2015 Nov;66(5):504-14. 7. Mahe M, et al. An FGFR3/MYC positive feedback loop provides new opportunities for targeted therapies in bladder cancers. EMBO Mol Med. 2018 Apr;10(4). pii: e8163.